5VA Stock Overview
A clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Vaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$80.50 |
| 52 Week High | US$108.00 |
| 52 Week Low | US$44.20 |
| Beta | 1.01 |
| 11 Month Change | -22.60% |
| 3 Month Change | 15.83% |
| 1 Year Change | 82.13% |
| 33 Year Change | 330.48% |
| 5 Year Change | n/a |
| Change since IPO | 83.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5VA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.0% | 0.8% | -1.3% |
| 1Y | 82.1% | -17.5% | 7.4% |
Return vs Industry: 5VA exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 5VA exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| 5VA volatility | |
|---|---|
| 5VA Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5VA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5VA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 254 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Vaxcyte, Inc. Fundamentals Summary
| 5VA fundamental statistics | |
|---|---|
| Market cap | €10.22b |
| Earnings (TTM) | -€484.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.7x
P/E RatioIs 5VA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5VA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$75.00m |
| Gross Profit | -US$75.00m |
| Other Expenses | US$432.65m |
| Earnings | -US$507.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5VA perform over the long term?
See historical performance and comparison